Results 131 to 140 of about 12,467 (245)

Development and Validation of a Novel Stability-Indicating RP-HPLC Method for Simultaneous Determination of Tezacaftor and Ivacaftor in Fixed Dose Combination [PDF]

, 2019
Narendra Singh, Parveen Bansal, Mukesh Maithani, Yashpal Singh Chauhan   +3 more
openalex   +1 more source

WS06.04 Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease [PDF]

, 2023
Chiara Premuda, Andrea Gramegna, Gianfranco Alicandro, Francesca Lucca, Mariangela Retucci, Francesco Amati, Sonia Volpi, Stefano Aliberti, Federico Blasi   +8 more
openalex   +1 more source

Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices. [PDF]

, 2015
O'Sullivan, Brian P, Orenstein, David M, Quinton, Paul M   +2 more
core   +1 more source

WS23.3 ICM is sensitive to detect potentiation of CFTR-mediated Cl− secretion in patients with cystic fibrosis and the G551D mutation treated with ivacaftor

, 2014
Simon Y. Graeber, Martin J. Hug, Olaf Sommerburg, Jochen G. Mainz, Andrea Heinzmann, Burkhard Tümmler, Marcus Mall   +6 more
openalex   +1 more source

Response to: ‘Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?’ by Jones and Barry [PDF]

, 2015
J.S. Elborn, Bonnie W. Ramsey, Claire Wainwright, Michael Boyle   +3 more
openalex   +1 more source

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup [PDF]

, 2016

core   +1 more source

144 Effect of treatment with ivacaftor on exhaled nitric oxide

, 2015
Hartmut Grasemann, Tanja Gonska, Julie Avolio, Elizabeth Tullis, Félix Ratjen   +4 more
openalex   +1 more source

Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States [PDF]

Sonia Graziano, E. Landau, Horst Mitmansgrubert, Marieke Verkleij, Anna M. Georgiopoulos, U. Borawska-Kowalczyk, Beth A. Smith, Christina J. Bathgate, Alexandra L. Quittner   +8 more
openalex   +1 more source

WS07.4 Effect of ivacaftor on airway bacterial community composition in CF patients with the G551D mutation

, 2016
D. Mooney, N.J. Ronan, G.G. Einarsson, E.T. Flanagan, J.A. Eustace, Michael M. Tunney, J.S. Elborn, B.J. Plant   +7 more
openalex   +1 more source

430 Ivacaftor treatment decreases prevalence of insoluble mucus flakes in young people with cystic fibrosis

, 2022
M. Markovetz, W. Boone, K. Rouillard, S. Stick, Christopher P. Esther, D. Hill   +5 more
openalex   +1 more source